ARTICLE | Clinical News
Liposomal Grb-2 regulatory update
May 4, 2015 7:00 AM UTC
FDA granted Orphan Drug designation to Liposomal Grb-2 from Bio-Path to treat acute myelogenous leukemia (AML). The liposomal antisense inhibitor of growth factor receptor-bound protein 2 (GRB2) expr...